🧪 Early-onset gastritis with ZOLBE 📊 CLDN18.2⁺ GC, 1L CT + ZOLBE (N=58) ⚠️ Gastritis in 89.7% (~8 weeks): erythema, exudate, edema 🌐 Mostly diffuse, multi-region (76.9%, 90.4%) 📌 Linked to anorexia and ↓albumin, improved without treatment cessation 👉
0
14
38
Replies
Neoadjuvant CTLA-4/PD-(L)1 vs Surgery +/-TTx in MSI Resectable Gastroesophageal Adenocarcinoma @JCO_ASCO
https://t.co/rzXnhO9XFK 🔎Patient Data Pooled Analysis: 197 pts, 49 ICIs, 27 FLOT 👉ICIs increase pCR & downstaging vs FLOT 🧐rationale for organ-sparing surgery or
1
12
44
Liver embolization in NETs – not a “low-risk” procedure ⚠️10 % major complications - lower than resection 💀 3 % mortality – similar to resection 💭Are we overlooking failure-to-rescue after embolization? Should we rethink where and how it’s done? https://t.co/zCPZPDKOyd
1
1
4
Congrats @Guv_onc on your incredible work with our @MDAndersonNews team over the past two years to #endcancer for our #crcsm pts! Such a pleasure to mentor you and watch you bring a really exciting neoadjuvant immunotherapy trial to our patients!! Excited to have you a part of
1
4
46
🚨 New Molecules to Watch at #ESMO25 (GI Cancers) 🔹 KRAS G12D inhibitors (GFH375, HRS-4642, INCB161734) 🔹 Zanzalintinib + Atezolizumab (STELLAR-303, mCRC) 🔹 Sirexatamab (DKN-01, MSS mCRC) 🔹 RC118 (CLDN18.2 ADC, Gastric/GEJ) 🔹 Telisotuzumab Adizutecan (c-MET ADC) 🔹
0
17
54